Yan Junya, Yu Jiayi, Wu Xiaowen, Xu Tianxiao, Yu Huan, Dai Jie, Ma Meng, Tang Huan, Xu Longwen, Chi Zhihong, Si Lu, Sheng Xinan, Cui Chuanliang, Kong Yan, Guo Jun
Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Renal cancer and Melanoma, Peking University Cancer Hospital & Institute, Beijing, China.
J Cancer. 2018 Mar 15;9(7):1267-1276. doi: 10.7150/jca.24013. eCollection 2018.
kinase is an essential serine/threonine kinase for mitosis and chromosome stability. The aberrant amplification and overexpression of are commonly observed in various types of cancer, including cutaneous melanoma. However, the status and the clinical significance of copy number (CN) in acral melanoma (AM) have not been fully elucidated. Four hundred and seventy-two AM samples were included in the study. CN was examined using the QuantiGenePlex DNA Assay. We analysed the relationship of CN to clinicopathological characteristics and survival of patients with AM. In this study, copy gain (set as more than 2.0 copies) was detected in 24.6% (116/472) of the samples. We did not observe any obvious correlation between clinicopathological characteristics and copy gain of the patients. However, patients with copy gain had a significantly shorter overall survival time (OS) and progression-free survival time (PFS) than those with normal CN (OS: = 0.022; PFS: < 0.001). Furthermore, multivariate Cox regression analysis showed that copy gain was an independent poor prognostic factor for patients with AM undergoing adjuvant interferon therapy. This study suggested that copy gain is an adverse prognostic factor for AM. Furthermore, copy gain may be a useful biomarker to predict the outcome of interferon therapy in patients with AM.
激酶是一种对有丝分裂和染色体稳定性至关重要的丝氨酸/苏氨酸激酶。其异常扩增和过表达在包括皮肤黑色素瘤在内的各种癌症类型中普遍存在。然而，肢端黑色素瘤（AM）中该基因拷贝数（CN）的状态及其临床意义尚未完全阐明。本研究纳入了472例AM样本。使用QuantiGenePlex DNA检测法检测CN。我们分析了AM患者的CN与临床病理特征及生存情况之间的关系。在本研究中，24.6%（116/472）的样本检测到该基因拷贝数增加（设定为超过2.0拷贝）。我们未观察到患者的临床病理特征与该基因拷贝数增加之间存在任何明显相关性。然而，该基因拷贝数增加的患者的总生存时间（OS）和无进展生存时间（PFS）明显短于该基因CN正常的患者（OS：P = 0.022；PFS：P < 0.001）。此外，多因素Cox回归分析表明，该基因拷贝数增加是接受辅助干扰素治疗的AM患者的独立不良预后因素。本研究提示该基因拷贝数增加是AM的不良预后因素。此外，该基因拷贝数增加可能是预测AM患者干扰素治疗结果的有用生物标志物。
